Stratos Wealth Partners’s Myriad Genetics MYGN Stock Holding History

Stratos Wealth Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-570	Closed	-$26K	–	1881
2018 Q3	$26K	Buy	+570	New	+$25.3K	﹤0.01%	1753
2018 Q2	–	Sell	-570	Closed	-$17K	–	1990
2018 Q1	$17K	Hold	570	–	–	﹤0.01%	2075
2017 Q4	$20K	Buy	+570	New	+$19.2K	﹤0.01%	1907
2014 Q4	–	Sell	-5,357	Closed	-$207K	–	523
2014 Q3	$207K	Hold	5,357	–	–	0.05%	280
2014 Q2	$210K	Buy	+5,357	New	+$199K	0.07%	283

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stratos Wealth Partners's MYGN Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 570 shares — an estimated $26K sold.

Stratos Wealth Partners first reported a position in MYGN in Q2 2014 and held it in 5 quarters. The position peaked at $210K in Q2 2014. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

Stratos Wealth Partners reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
Stratos Wealth Partners sold 570 Myriad Genetics shares in Q4 2018, an estimated $26K.
Stratos Wealth Partners first reported a position in Myriad Genetics in Q2 2014 and held it in 5 quarters.
Stratos Wealth Partners's Myriad Genetics position peaked at $210K in Q2 2014.
264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.